Recombinant Proteins Market Size was valued at USD 2.75 Billion in 2022. The Recombinant Proteins Market industry is projected to grow from USD 2.97 Billion in 2023 to USD 5.49 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.00% during the forecast period (2024 - 2032). The increased investment by healthcare organizations in research and development, the rising prevalence of chronic diseases and the proliferation of regulatory bodies focusing on reducing viral infections are expected to be significant market drivers for the Recombinant Proteins Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Rising incidence of chronic diseases and increasing investments in research and development are driving the market growth.
Market CAGR for Recombinant Proteins is driven by the rising incidence of chronic diseases and increasing investments in research and development. The increasing prevalence of chronic illnesses has fueled the demand for precise and efficient protein-based therapeutic interventions. According to the American Cancer Society, the yearly incidence and mortality rates of cancer, including lung, breast, colorectal, prostate and skin cancers, remain significant. Several factors contribute to cancer risk, such as tobacco consumption, poor dietary habits, sedentary lifestyle, excessive sun exposure and exposure to certain environmental toxins. Notably, breast, lung, bronchus, prostate and colorectal cancers collectively represent nearly half of all new cancer cases in the United States, while lung, bronchus, colorectal, pancreatic and breast cancers account for almost half of all cancer-related deaths. In 2022, approximately 1.9 million new cancer cases were diagnosed in the US, resulting in 609,360 deaths. Cancer stands as the second leading cause of death in the country. Furthermore, China recorded an estimated 4,820,000 new cancer cases and 3,210,000 cancer-related deaths in 2022, as per the latest data. According to the Indian Council of Medical Research's National Cancer Registry Programme (ICMR-NCRP), cervical cancer cases in India surpassed 340,000 in 2023. India witnessed over 1.41 million new cancer cases and more than 910,000 deaths in 2022, with breast cancer being the most prevalent, according to the World Health Organization (WHO).
The market growth is bolstered by increasing investments in research and development aimed at introducing novel recombinant protein therapeutics. For example, a May 2022 update from the National Institutes of Health (NIH) in the United States revealed that approximately USD 1,021 million was allocated for research and development funding for autoimmune diseases in 2021, with projections indicating a further increase to USD 1,061 million in 2022. Consequently, this surge in investment is driving the development of recombinant protein-based medications, thus propelling the expansion of the analyzed market. As a result, it is anticipated that throughout the projection period, demand for the Recombinant protein market will increase due to the Rising incidence of chronic diseases and increasing investments in research and development. Thus, driving the Recombinant Proteins Market revenue.
The Recombinant Proteins Market segmentation, based on Product, includes Hormones, Growth Factors, Antibody, Enzymes and Other Types of Products. The antibody segment dominated the market, accounting for 58% of market revenue. The growth of this segment is fueled by the rising prevalence of diabetes and the expanding use of antibodies. For example, the International Diabetes Federation (IDF) reported in 2021 that ly, there were 537 million cases of diabetes, with projections indicating an increase to 783 million cases by 2045. Therefore, the segment's expansion is attributed to the surge in chronic diseases like diabetes, which is driving demand for recombinant antibodies.
The Recombinant Proteins Market segmentation, based on the Application, includes Research Application, Therapeutic Use and Biotechnology Industry. The therapeutic use segment dominated the market, accounting for 58% of market revenue. Protein therapeutics provide highly efficient treatments for conditions such as diabetes, cancer, infectious diseases, hemophilia and anemia. The International Diabetes Federation reports that approximately 537 million individuals aged 20-79 had diabetes in 2021. Projections indicate that the diabetic population will reach 643 million by 2030 and 783 million by 2045. With the substantial growth in the diabetic population, the demand for recombinant proteins in the therapeutics segment is expected to experience significant growth in the upcoming years.
Figure 1: Recombinant Proteins Market, by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The anticipated expansion of the Recombinant Proteins market in North America can be attributed to several key factors. Progressive research aimed at treating various neurodegenerative conditions such as Alzheimer's disease and dementia is contributing to the expansion of the analyzed market. Considerable time and resources in Alzheimer's research have been allocated to studying a protein known as amyloid, as many researchers in the field believe that targeting amyloid is pivotal in addressing the root cause of the disease. This focus on amyloid is anticipated to drive the demand for therapies targeting this protein. For instance, an article published in the journal ANC in April 2022 highlighted the significance of plaque-associated proteins in understanding amyloid plaque development, offering potential biomarkers or therapeutic targets for Alzheimer's disease. Additionally, the growing number of clinical trials conducted in the country is boosting demand for the analyzed market. For instance, in 2022, Clinicaltrials.gov reported approximately 15,316 registered clinical trials in the United States involving biopharmaceuticals. This uptrend in clinical trial activity is expected to fuel market growth in the country.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil.
Figure 2: RECOMBINANT PROTEINS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Recombinant Proteins Market accounts for the second-largest market share as Advancements in recombinant DNA technology, cell culture methodologies, protein expression systems and increased accessibility to high-yield expression systems such as mammalian cell lines, yeast and bacteria all contribute to driving growth in the Recombinant Proteins Market. Europe hosts several countries renowned for their high focus on research and development (R&D), including the UK, Germany and Denmark. For instance, according to EuroDev, the pharmaceutical industry in Germany allocates over USD 6.74 billion (EUR 6.2 billion) annually to R&D and conducted approximately 499 clinical trials funded by research-based pharmaceutical companies in 2019. Further, the German Recombinant Proteins Market held the largest market share and the UK Recombinant Proteins Market was the fastest-growing market in the European region.
The Asia-Pacific Recombinant Proteins Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing expansion driven by an upsurge in both public and private funding for research and development in recombinant protein studies, favorable government regulations and the increasing prevalence of target diseases among an aging population. In Asia and the Pacific, the number of older individuals is expected to more than double from 630 million in 2020 to approximately 1.3 billion by 2050. In 2020, 13.6% of the population in Asia and the Pacific was aged 60 years or older and by 2050, this demographic is projected to represent one-quarter of the population. Moreover, advancements in proteomic and genomic research techniques are driving growth in the region. Moreover, China’s Recombinant Proteins Market held the largest market share and the Indian Recombinant Proteins Market was the fastest-growing market in the Asia-Pacific region.
Recombinant Proteins Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Recombinant Proteins market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Recombinant Proteins industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Recombinant protein industry to benefit clients and increase the market sector. In recent years, the Recombinant Proteins industry has offered some of the most significant advantages to the fields of medicine, biotechnology and pharmaceuticals. Major players in the Recombinant Proteins Market, including Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC are attempting to increase market demand by investing in research and development operations.
Merck KGaA, a subsidiary of E. Merck KG, operates as a science and technology company. Its activities encompass the discovery, development and manufacturing of prescription drugs targeting cancer, multiple sclerosis and infertility. Additionally, Merck is involved in the development of various materials, such as liquid crystal mixtures and organic light-emitting diode (OLED) materials, as well as cosmetic active ingredients and pigments for coatings. Moreover, the company offers a diverse range of products, including lab water systems, gene editing tools, cell lines, antibodies, microbiology and biomonitoring products, along with test assays, analytical reagents and flow cytometry kits and instruments, providing comprehensive solutions across various sectors including healthcare, performance materials and life sciences. With a presence spanning Europe, North America, Asia-Pacific, Latin America and the Middle East and Africa, Merck is headquartered in Darmstadt, Hesse, Germany. In February 2020, Merck KGaA (Germany) collaborated with Donghao Lansheng (Group) Co., Ltd. on a project based in China. This partnership aimed to evaluate a new import policy in China, which is intended to streamline the clearance process for research items used in biomedical innovation and analytical purposes via customs, facilitating Merck's operations in the country.
Thermo Fisher Scientific Inc. (Thermo Fisher) is a leading provider of medical equipment, analytical instruments, reagents, consumables, software and services designed to address complex analytical challenges across various fields, including research, diagnostics and clinical laboratories. The company offers comprehensive solutions for cellular analysis, biology, flow cytometry and synthetic biology. Its product portfolio encompasses technologies for mass spectrometry, genetic sequencing, electron microscopy, as well as protein and molecular biology research. Thermo Fisher serves a diverse customer base, including pharmaceutical and biotech companies, academic and research institutions, clinical diagnostic laboratories, government agencies and sectors focusing on environmental, industrial quality and process control. Its products and services are distributed through a variety of channels, including direct sales force, e-commerce platforms and third-party distributors across the Americas, Asia-Pacific and Europe. Headquartered in Waltham, Massachusetts, USA, Thermo Fisher continues to expand its presence. In May 2023, Thermo Fisher Scientific Inc. (USA) and the National Research and Innovation Agency of Indonesia (BRIN) entered into a Memorandum of Understanding (MOU) aimed at facilitating and enhancing Indonesia's national research and innovation infrastructure and capabilities.
Key companies in the Recombinant Proteins Market include
Recombinant Proteins Industry Developments
July 2023: Dyadic International, Inc. provided an update on its Phase 1 Clinical Trial for the DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate. The Data Safety Monitoring Board (DSMB) conducted an interim analysis of Day 29 data for both low and high-dose groups, confirming the absence of significant vaccine-related safety concerns.
April 2019: Elpiscience BioPharma collaborated with Bio-Techne Corp. (U.S.) and Bio-Techne Corp. (China). Through this partnership, Elpiscience gained access to Bio-Techne's extensive range of recombinant antibodies for the development of preclinical, clinical and commercial biopharmaceuticals aimed at creating anticancer treatments.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 2.75 Billion |
| Market Size 2023 | USD 2.97 Billion |
| Market Size 2032 | USD 5.49 Billion |
| Compound Annual Growth Rate (CAGR) | 8.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors and Trends |
| Segments Covered | Product, Application and Region |
| Geographies Covered | North America, Europe, Asia Pacific and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil |
| Key Companies Profiled | Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC |
| Key Market Opportunities | · Increasing focus on research and development |
| Key Market Dynamics | · Surge in chronic disease and chronic disease-related mortalities worldwide |
Frequently Asked Questions (FAQ) :
The Recombinant Proteins Market size was valued at USD 2.97 Billion in 2023.
The Recombinant protein market is projected to grow at a CAGR of 8.00% during the forecast period, 2024-2032.
North America had the largest share of the market.
The key players in the market are Abbvie Inc., Amgen Inc., Bio-Rad Laboratories Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, Sanofi SA, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline PLC.
The Antibody segment dominated the market in 2023.
The Therapeutic Use segment had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
